Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats

Figure 1 Protective effect of irsogladine maleate on gastric mucosal lesions induced by indomethacin in rats. Stomachs from rats not pretreated with irsogladine maleate (A) and pretreated with irsogladine maleate at the doses of 1 mg/kg (B), 3 mg/kg (C) or 10 mg/kg (D), respectively, 1 h before administration of indomethacin. Nine rats were used in each group.

Figure 2 Protective effect of irsogladine maleate on gastric mucosal lesions induced by indomethacin in rats. Each value represents the mean ± SE for 9 rats. ^aP < 0.05 and ^bP < 0.01 vs control group.

Figure 3 Effect of irsogladine maleate on gastric mucosal TNF-α (A), IL-1β (B), IL-8 (C) and MPO (D) induced by indomethacin in rats. Each value represents the mean ± SE for 9 rats, ^bP < 0.01 vs control group, ^dP < 0.01 vs normal group.